COMP <GO>
INSP vs ABBV // RSI-14 & 200D SMA MOMENTUM
Inspire Medical Systems Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: INSP 7
— ABBV 5
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $71.18 (+0.30%) • MKT CAP: $2.06B
rsi-technicals
53.5
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
rsi-technicals
65.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSP VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSP | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 85.40% | 70.20% | +15.20 | INSP | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 29.00% | -23.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.3x | 33.3x | -10.00 | INSP | /valuation <GO> |
| Free Cash Flow Yield | 3.81% | 3.47% | +0.34 | INSP | /fcf-yield <GO> |
| Operating Margin | 5.60% | 24.60% | -19.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 15.90% | 6.90% | +9.00 | INSP | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | 8.60% | +5.00 | INSP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.40 | 5.33 | +6.07 | INSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 53.5 | 65.1 | -11.60 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 113.1x | -101.20 | INSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.06B | $513.86B | -$511.80B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSP REV | ABBV REV | INSP GROSS % | ABBV GROSS % | INSP FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $912.0M | $61.16B | 85.4% | 70.2% | $78.5M | $17.82B |
| FY 2024 | $802.8M | $56.33B | 84.7% | 70.0% | $91.1M | $17.83B |
| FY 2023 | $624.8M | $54.32B | — | — | $24.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSP // BETA —
ABBV // BETA 1.15